Valbiotis appoints Josep Infesta
Valbiotis, a French research and development company committed to preventing and combating metabolic diseases, today on 24 January the appointment of Josep Infesta as Head of Global Business Development.
He will lead the development and negotiations of partnerships with players specialized in health, to introduce VALEDIA® for reducing the risk of type 2 diabetes in prediabetic populations. His proven marketing expertise will enable VALBIOTIS to determine the scope of the target markets for VALEDIA® in Europe, the United States and Canada. Phase IIA results for VALEDIA in prediabetes are expected in mid-2019, with a launch objective set for 2021. Josep INFESTA will be supported in his missions by a dedicated team of AEC Partners, a firm specializing in life sciences for market access, licensing and strategy consulting. This team of AEC Partners will be under the direct coordination of Jordi ESCLUSA, co-founder of the firm.
Biocytogen Co Ltd
Draupnir Bio ApS